Xolair, which blocks the allergic triggers behind 80 per cent of attacks, has been approved for NHS use by the National Institute for Health and Clinical Excellence. Trials have shown the drug can halve the risks of asthma attacks and experts have hailed it a ‘wonder treatment’.
It is the first asthma injection that has been genetically engineered to block IgE – the immunoglobulin responsible for the allergic process which can lead to attacks. The new drug stops the body overreacting to inhaled allergic particles such as tree and grass pollens, cat fur and house-dust mites. Fortnightly or monthly injections have been shown to cut the risk of attacks in those with severe asthma by 55 per cent and reduce hospital admissions by half.
There are 5 million people in Britain with asthma, costing the economy and health service around £8 billion a year. The condition kills more than 1,400 people annually and a further 69,000 are put in hospital, in many cases for weeks.
Professor Britton comments: “Xolair is a breakthrough, the most important advance in asthma treatment for a decade. We can now prescribe Xolair for those severe allergic asthmatics, who are in and out of hospital with significant exacerbations. Our experience with the drug has shown that it has a dramatic effect on the quality of life for this group of unfortunate patients.”
Media enquiries: Peter La, Press Office at the University of Surrey, Tel: 01483 689191 or E-mail: email@example.com
Stuart Miller | alfa
Biofilm discovery suggests new way to prevent dangerous infections
23.05.2017 | University of Texas at Austin
Another reason to exercise: Burning bone fat -- a key to better bone health
19.05.2017 | University of North Carolina Health Care
The world's highest gain high power laser amplifier - by many orders of magnitude - has been developed in research led at the University of Strathclyde.
The researchers demonstrated the feasibility of using plasma to amplify short laser pulses of picojoule-level energy up to 100 millijoules, which is a 'gain'...
Staphylococcus aureus is a feared pathogen (MRSA, multi-resistant S. aureus) due to frequent resistances against many antibiotics, especially in hospital infections. Researchers at the Paul-Ehrlich-Institut have identified immunological processes that prevent a successful immune response directed against the pathogenic agent. The delivery of bacterial proteins with RNA adjuvant or messenger RNA (mRNA) into immune cells allows the re-direction of the immune response towards an active defense against S. aureus. This could be of significant importance for the development of an effective vaccine. PLOS Pathogens has published these research results online on 25 May 2017.
Staphylococcus aureus (S. aureus) is a bacterium that colonizes by far more than half of the skin and the mucosa of adults, usually without causing infections....
Physicists from the University of Würzburg are capable of generating identical looking single light particles at the push of a button. Two new studies now demonstrate the potential this method holds.
The quantum computer has fuelled the imagination of scientists for decades: It is based on fundamentally different phenomena than a conventional computer....
An international team of physicists has monitored the scattering behaviour of electrons in a non-conducting material in real-time. Their insights could be beneficial for radiotherapy.
We can refer to electrons in non-conducting materials as ‘sluggish’. Typically, they remain fixed in a location, deep inside an atomic composite. It is hence...
Two-dimensional magnetic structures are regarded as a promising material for new types of data storage, since the magnetic properties of individual molecular building blocks can be investigated and modified. For the first time, researchers have now produced a wafer-thin ferrimagnet, in which molecules with different magnetic centers arrange themselves on a gold surface to form a checkerboard pattern. Scientists at the Swiss Nanoscience Institute at the University of Basel and the Paul Scherrer Institute published their findings in the journal Nature Communications.
Ferrimagnets are composed of two centers which are magnetized at different strengths and point in opposing directions. Two-dimensional, quasi-flat ferrimagnets...
24.05.2017 | Event News
23.05.2017 | Event News
22.05.2017 | Event News
29.05.2017 | Life Sciences
26.05.2017 | Life Sciences
26.05.2017 | Life Sciences